Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase

被引:163
作者
Zhang, W
Wang, TG
Qin, LY
Gao, HM
Wilson, B
Ali, SF
Zhang, WQ
Hong, JS
Liu, B
机构
[1] Univ Florida, Coll Pharm, Dept Pharmacodynam, Gainesville, FL 32610 USA
[2] NIEHS, Lab Pharmacol & Chem, Res Triangle Pk, NC 27709 USA
[3] First Clin Hosp, Dept Neurol, Dalian, Peoples R China
[4] Dalian Med Univ, Dept Physiol, Dalian, Peoples R China
[5] US FDA, Neurochem Lab, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA
关键词
reactive oxygen species; microglia; dopamine; substantia nigra; morphinan;
D O I
10.1096/fj.03-0983fje
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Parkinson's disease (PD) is a neurodegenerative movement disorder characterized by a progressive loss of dopaminergic neurons in the substantia nigra and depletion of the neurotransmitter dopamine in the striatum. Progress in the search for effective therapeutic strategies that can halt this degenerative process remains limited. Mechanistic studies using animal systems such as the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rodent PD model have revealed the involvement of the brain's immune cells and free radical-generating processes. We recently reported that dextromethorphan (DM), a widely used anti-tussive agent, attenuated endotoxin-induced dopaminergic neurodegeneration in vitro. In the current study, we investigated the potential neuroprotective effect of DM and the underlying mechanism of action in the MPTP rodent PD model. Mice (C57BL/6J) that received daily MPTP injections (15 mg free base/kg body weight, s.c.) for 6 consecutive days exhibited significant degeneration of the nigrostriatal dopaminergic pathway. However, the MPTP-induced loss of nigral dopaminergic neurons was significantly attenuated in those mice receiving DM (10 mg/kg body weight, s.c.). In mesencephalic neuron-glia cultures, DM significantly reduced the MPTP-induced production of both extracellular superoxide free radicals and intracellular reactive oxygen species (ROS). Because NADPH oxidase is the primary source of extracellular superoxide and intracellular ROS, we investigated the involvement of NADPH oxidase in the neuroprotective effect of DM. Indeed, the neuroprotective effect of DM was only observed in the wild-type but not in the NADPH oxidase-deficient mice, indicating that NADPH oxidase is a critical mediator of the neuroprotective activity of DM. More importantly, due to its proven safety record of long-term clinical use in humans, DM may be a promising agent for the treatment of degenerative neurological disorders such as PD.
引用
收藏
页码:589 / +
页数:21
相关论文
共 47 条
[11]   Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra [J].
Feng, ZH ;
Wang, TG ;
Li, DD ;
Fung, P ;
Wilson, BC ;
Liu, B ;
Ali, SF ;
Langenbach, R ;
Hong, JS .
NEUROSCIENCE LETTERS, 2002, 329 (03) :354-358
[12]   Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease [J].
Gao, HM ;
Liu, B ;
Zhang, WQ ;
Hong, JS .
FASEB JOURNAL, 2003, 17 (11)
[13]  
Gao HM, 2003, J NEUROSCI, V23, P6181
[14]   Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: Relevance to the etiology of Parkinson's disease [J].
Gao, HM ;
Hong, JS ;
Zhang, WQ ;
Liu, B .
JOURNAL OF NEUROSCIENCE, 2003, 23 (04) :1228-1236
[15]   Lipopolysaccharide (LPS)-induced dopamine cell loss in culture:: roles of tumor necrosis factor-α, interleukin-1β, and nitric oxide [J].
Gayle, DA ;
Ling, ZD ;
Tong, CW ;
Landers, T ;
Lipton, JW ;
Carvey, PM .
DEVELOPMENTAL BRAIN RESEARCH, 2002, 133 (01) :27-35
[16]   DEXTROMETHORPHAN REDUCES NEOCORTICAL ISCHEMIC NEURONAL DAMAGE INVIVO [J].
GEORGE, CP ;
GOLDBERG, MP ;
CHOI, DW ;
STEINBERG, GK .
BRAIN RESEARCH, 1988, 440 (02) :375-379
[17]   Induction of gp91-phox, a component of the phagocyte NADPH oxidase, in microglial cells during central nervous system inflammation [J].
Green, SP ;
Cairns, B ;
Rae, J ;
Errett-Baroncini, C ;
Hongo, JAS ;
Erickson, RW ;
Curnutte, JT .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2001, 21 (04) :374-384
[18]   Mitochondrial dysfunction in Parkinson's disease [J].
Greenamyre, JT ;
MacKenzie, G ;
Peng, TI ;
Stephans, SE .
MITOCHONDRIA AND CELL DEATH, 1999, 66 :85-97
[19]  
Haberecht MF, 1997, J NEUROSCI RES, V47, P416
[20]   Understanding cell death in Parkinson's disease [J].
Jenner, P ;
Olanow, CW .
ANNALS OF NEUROLOGY, 1998, 44 (03) :S72-S84